Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

[1]  J. Issa,et al.  First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS). , 2004 .

[2]  R M Stone,et al.  Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome , 2004, Leukemia.

[3]  F. Mandelli,et al.  Survival of elderly patients with acute myeloid leukemia. , 2004, Haematologica.

[4]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[5]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[6]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[7]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Rodenhuis,et al.  At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  P F Thall,et al.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.

[10]  M. L. Thomas.  Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. , 1998, Leukemia research.

[11]  P. Jones,et al.  Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. , 1998, Cancer research.

[12]  E. Dann,et al.  Selective discharge of patients with acute myeloid leukemia during chemotherapy‐induced neutropenia , 1996, American journal of hematology.

[13]  U. Germing,et al.  [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. , 1996, Deutsche medizinische Wochenschrift.

[14]  D. G. Altman,et al.  Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.

[15]  J. Uberti,et al.  Allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. , 1994, Leukemia & lymphoma.

[16]  A. Ghirarduzzi,et al.  Cost/benefit relationship in 46 cases of myelodysplastic syndrome (RAEB and RAEB-T): a quality assurance analysis in clinical haematology. , 1993, Haematologica.

[17]  E. Estey,et al.  All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Konstantopoulos,et al.  Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. , 1989, Anticancer research.

[20]  R. Simon,et al.  A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.